Aisa Pharma’s AISA-021 shows promising Phase 2 signals in systemic sclerosis Raynaud’s. Discover what the RECONNOITER data could mean for future treatment.
HR HealthCare launches the EZ-Protect hydrophilic catheter line to reduce infection risk and improve portability. Discover what it means for urology care.
Lone Star Funds acquires Lonza's CHI division in a carve-out reshaping pharma capsule supply. Read what this means for the CDMO market.
MindWalk launches B Cell Llama, a VHH nanobody platform for bispecific drug design. Peer-reviewed data raises key questions about function, immunogenicity, and AI.
Savara's molgramostim BLA faces no FDA adcom. Analysis of what the August 2026 PDUFA date means for autoimmune PAP treatment access. Read more.
European regulators approve retifanlimab for advanced anal cancer. Discover what this means for immunotherapy treatment strategies in rare oncology today.
FDA approves Bristol Myers Squibb’s Sotyktu for psoriatic arthritis. Discover what TYK2 inhibition means for autoimmune treatment and future rheumatology drugs.
Great Novel Therapeutics launches Phase I trial of GNTbm-38 after FDA IND approval. Discover what this epigenetic cancer immunotherapy could change.
Neuspera Medical's 12-month pivotal SNM trial shows 94% responder rates and zero infections. Analysing what this means for the SNM market. Read more.
FDA approves J&J's teclistamab plus daratumumab for relapsed myeloma from second line. Analyse the MajesTEC-3 data, safety profile, and what this changes for treatment.